SCHEMBL2385123

SCHEMBL2385123

CC(=O)OCc1cccc(O)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.66
CYP3A4 P08684 3/20 0.52
ENPP2 Q13822 1/20 0.48
IDH1 O75874 1/20 0.47
TYR P14679 1/20 0.46
SPR P35270 1/20 0.46
CHRM2 P08172 1/20 0.46
CHRM1 P11229 1/20 0.46
CHRM3 P20309 1/20 0.46
DRD2 P14416 1/20 0.46
DRD1 P21728 1/20 0.46
TAAR1 Q96RJ0 1/20 0.46
CTBP2 P56545 1/20 0.45
GABRA1 P14867 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45
GABRB2 P47870 1/20 0.45
CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6709375 0.90 ALDH1A1 (0.73) ALDH1A1CYP3A4IDH1MAPK1
SCHEMBL27608519 0.84 TYR (0.61) ALDH1A1CYP3A4TYRSPRCHRM2
SCHEMBL6903259 0.83 ALDH1A1 (0.63) ALDH1A1CYP3A4IDH1CTBP2
SCHEMBL16154053 0.83 ALDH1A1 (0.63) ALDH1A1CYP3A4IDH1MAPK1
SCHEMBL801397 0.83 ALDH1A1 (0.63) ALDH1A1CYP3A4IDH1
SCHEMBL7671543 0.83 ALDH1A1 (0.63) ALDH1A1CYP3A4IDH1
SCHEMBL7671540 0.83 ALDH1A1 (0.63) ALDH1A1CYP3A4IDH1
E1501 SCHEMBL9081313 0.82 ALDH1A1 (0.88) ALDH1A1IDH1CYP1A2MAPK1
SCHEMBL1904651 0.82 ALDH1A1 (0.44) ALDH1A1CYP3A4ENPP2TYRSPR
SCHEMBL2659547 0.81 ALDH1A1 (0.61) ALDH1A1CYP3A4ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024199069-A1 POLYARYL-CONTAINING MACROCYCLIC COMPOUND AND USE THEREOF 浙江养生堂天然药物研究所有限公司 2024-10-03 WO disclosed
CN-118724916-A Polyaryl-containing macrocyclic compounds and uses thereof 浙江养生堂天然药物研究所有限公司 2024-10-01 CN disclosed
US-20170101429-A1 METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-04-13 US disclosed
WO-2016004704-A1 GASTRODIN PRODUCTION PROCESS 江苏汉斯通药业有限公司 2016-01-14 WO disclosed
CN-102007118-B Pyrrolidinone glucokinase activators HOFFMANN LA ROCHE 2014-12-31 CN disclosed
CN-101326161-B Novel compounds ASTRAZENECA AB 2013-04-17 CN disclosed
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2364984-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-09-14 EP disclosed
CN-1875002-B Phenyl derivatives as PPAR agonists HOFFMANN LA ROCHE 2011-08-03 CN disclosed
CN-101296892-A PPAR active compounds PLEXXIKON INC (US) 2008-10-29 CN disclosed
CN-101031540-A Hexafluoroisopropanol substituted ether derivatives HOFFMANN LA ROCHE (CH) 2007-09-05 CN disclosed
CN-1310890-C Isoquinoline derivatives HOFFMANN LA ROCHE (CH) 2007-04-18 CN disclosed
CN-1875002-A Phenyl derivatives as PPAR agonists HOFFMANN LA ROCHE (CH) 2006-12-06 CN disclosed
CN-1795193-A N-acyl nitrogen heterocyles as ligands of peroxisome proliferator-activated receptors NOVARTIS AG (CH) 2006-06-28 CN disclosed
CN-1649844-A Isoquinoline derivatives HOFFMANN LA ROCHE (CH) 2005-08-03 CN disclosed
US-6348478-B1 BLOOD COAGULATION FACTORS AND ANTICOAGULANTS TEIJIN LIMITED (JP) 2002-02-19 US disclosed
EP-1043311-A1 BIPHENYLAMIDINE DERIVATIVES TEIJIN LIMITED (JP) 2000-10-11 EP disclosed
CN-1074681-A Chromene and relevant leukotriene B 4Antagonist PFIZER (US) 1993-07-28 CN disclosed
US-4709081-A ETHERIFICATION, HYDROLYSIS CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA R.T. (HU) 1987-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 ALDH1A1 2376/4885CYP3A4 1260/4885ENPP2 2110/4885
US-20170101429-A1 METAL ORGANIC FRAMEWORKS COMPRISING A PLURALITY OF SBUS WITH DIFFERENT METAL IONS AND/OR A PLURALITY OF ORGANIC LINKING LIGANDS WITH DIFFERENT FUNCTIONAL GROUPS EPCAM, SOD1, SBDS ALDH1A1 1971/4885CYP3A4 3614/4885ENPP2 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.